04.07.25 -- What Biotechs Learn From Takeda's Internal Manufacturing Competition

Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based and biochemical assays, and more.

Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery along with potential strategies to address these issues.

It is important to develop robust, reliable processes to safeguard APIs. Review several best practices for providing patients with the highest quality treatment that meets their therapeutic requirements.

Vince Kosewski, KALA BIO, and Kishore Hotha, Dr. Hotha’s Life Sciences, remind us that our recent outsourcing fears should remind us of the fundamentals for approaching supply-chain decision-making.

This model class transfers real-time information in one direction, and it can help bridge the gap between digital model and fully functioning digital twin.

The rapid scale-up of mRNA drug manufacturing is impressive but has exposed supply chain vulnerabilities for essential ingredients like lipids.

Begin optimizing biopharmaceutical manufacturing with integrated, sustainable, and cost-effective solutions that enhance efficiency and facility utilization.

Blending pharmaceuticals and medical devices into a single product offers immense potential for patient care, but manufacturing these combination products presents unique hurdles.

Harness the power of platform strategies and proven expertise, streamlining your drug development process while ensuring quality, consistency, and efficiency at every step.

For bispecific antibodies (bsAbs), the goal of downstream process development is to develop a method for obtaining highly purified bsAbs with optimal recovery and quality.

The biopharmaceutical industry faces a multitude of challenges. Learn how a collaborative outsourcing partnership based on trust and transparency can foster efficient and high-quality drug production.

Many CDMOs cannot handle complex recombinant proteins, which often require a CLD process fully integrated with other CDMO components, including analytics and formulation development.

In situations calling for the reliable labeling of medical products, the limitations of fully automatic machines are quickly exposed by extremely small batches and/or products prone to overbalancing.

Backed by Lonza’s more than 30 years’ expe­rience and expertise, we offer our customers a full “one-stop-shop” service package at all stages of development and production.

Witness how our parallel development service works seamlessly with our existing antibody capabilities, helping to accelerate your ADC program and reach market faster.

Corvus, a small biotech developing precision medicines, primarily for oncology patients, was seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab.

The use of cyclic olefin copolymer (COC) allows for much greater design flexibility, and the creation of more robust containers, whilst also allowing the removal of potentially harmful materials.

Discover why partners trust Lifecore Biomedical for safe, high-quality injectable pharmaceuticals as they celebrate 60 years of manufacturing excellence and innovation.